12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PDC31: Phase I data

A Phase I trial in healthy women with primary dysmenorrhea showed that PDC31 dose-dependently relieved pain and reduced intrauterine pressure. PDC31 was well tolerated with no dose-limiting toxicities (DLTs) reported. PDC said it...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >